HCA Healthcare (HCA) Stock Forecast & Price Target

$415.77 +10.79 (+2.66%)

As of 01:09 PM Eastern

Compare

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
1

Hold
8

Buy
14

Based on 23 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 8 have given a hold rating, and 14 have given a buy rating for HCA.

Consensus Price Target

$465.59
11.98% Upside

According to the 23 analysts' twelve-month price targets for HCA Healthcare, the average price target is $465.59. The highest price target for HCA is $579.00, while the lowest price target for HCA is $380.00. The average price target represents a forecasted upside of 11.98% from the current price of $415.77.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HCA Analyst Ratings Over Time

Type	Current Forecast 8/18/25 to 8/18/26	1 Month Ago 7/19/25 to 7/19/26	3 Months Ago 5/20/25 to 5/20/26	1 Year Ago 8/18/24 to 8/18/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	16 Buy rating(s)	7 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$465.59	$486.14	$515.77	$398.58
Forecasted Upside	11.98% Upside	30.82% Upside	29.89% Upside	1.20% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Healthcare Companies	Broader Market
Consensus Rating Score	2.57	2.29	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	14.81% Upside	796.70% Upside	12.16% Upside
News Sentiment Rating	Neutral News See Recent HCA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/3/2026	Wells Fargo & Company 3 of 5 stars	Stephen Baxter 4 of 5 stars	Boost Target	Equal Weight	$369.00 ➝ $381.00	-7.87%
7/28/2026	The Goldman Sachs Group 3 of 5 stars	Scott Fidel Not Rated	Lower Target	Buy	$558.00 ➝ $485.00	+24.44%
7/28/2026	Mizuho 3 of 5 stars	Ann Hynes 2 of 5 stars	Lower Target	Outperform	$525.00 ➝ $475.00	+21.88%
7/27/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A.J. Rice Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$635.00 ➝ $579.00	+49.09%
7/27/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$476.00	+22.57%
7/27/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Hettenbach Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$425.00 ➝ $380.00	-2.15%
7/27/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David MacDonald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$535.00 ➝ $495.00	+27.98%
7/27/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$435.00	+12.46%
7/27/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Wiederhorn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$520.00 ➝ $485.00	+26.30%
7/27/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Gillmor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$475.00 ➝ $435.00	+13.79%
The cat is out the bag (Ad) Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. Watch Porter Stansberry's full investigation into the Final Displacement now
7/27/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$402.00 ➝ $387.00	+1.23%
7/27/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ha Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$396.00 ➝ $393.00	+2.80%
7/15/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lance Wilkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$450.00	+23.47%
7/7/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$528.00	+23.26%
7/7/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$588.00 ➝ $525.00	+25.90%
6/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Langston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$500.00 ➝ $431.00	+14.99%
6/9/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy (B-) ➝ Hold (C+)
5/19/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$535.00 ➝ $490.00	+19.92%
5/4/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$560.00 ➝ $500.00	+15.88%
4/27/2026	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Raj Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$560.00 ➝ $530.00	+19.56%
4/27/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$573.00 ➝ $500.00	+13.32%
11/27/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
10/27/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanna Gajuk Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$430.00 ➝ $470.00	+1.71%
7/28/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Lake Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
4/9/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:10 PM ET.

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 17, 2026. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

The current stock price is around $387, which is significantly lower than its one-year high, indicating potential for price appreciation.
HCA Healthcare, Inc. reported a strong quarterly earnings per share (EPS) of $7.59, exceeding expectations, which reflects robust financial performance.
The company has shown a year-over-year revenue increase of 8.7%, suggesting growth in its operations and market demand for its services.
HCA Healthcare, Inc. has a relatively low price-to-earnings (PE) ratio of 13.59, indicating that the stock may be undervalued compared to its earnings, making it an attractive investment opportunity.
The company has a consistent dividend payout, with an annualized dividend yield of 0.8%, providing investors with a steady income stream.

HCA Healthcare
Bear Case

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

HCA Healthcare, Inc. has a negative return on equity of 244.79%, which may raise concerns about the company's ability to generate profit from shareholders' equity.
The stock has a beta of 1.12, indicating that it is more volatile than the market, which could lead to higher risk for investors.
Despite recent revenue growth, the company has a net margin of 8.77%, which may suggest challenges in maintaining profitability.
Analysts have mixed ratings on the stock, with some suggesting a "Hold" rating, indicating uncertainty about its future performance.
Recent price target adjustments by analysts show a range of opinions, with some lowering their expectations, which could signal potential headwinds for the stock.

HCA Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $465.59, with a high forecast of $579.00 and a low forecast of $380.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There is currently 1 sell rating, 8 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted upside of 11.98% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 2 downgrades by analysts.

HCA Healthcare has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, KeyCorp, Mizuho, Morgan Stanley, Oppenheimer, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like HCA Healthcare more than other "healthcare" companies. The consensus rating for HCA Healthcare is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

This page (NYSE:HCA) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HCA Analyst Ratings Over Time

HCA Analyst Recommendations By Month

HCA Price Targets by Month

HCA Healthcare Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

HCA Healthcare
Bull Case

HCA Healthcare
Bear Case

HCA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HCA Analyst Ratings Over Time

HCA Analyst Recommendations By Month

HCA Price Targets by Month

HCA Healthcare Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

HCA Healthcare Bull Case

HCA Healthcare Bear Case

HCA Forecast - Frequently Asked Questions

What is HCA Healthcare's forecast for 2026?

Should I buy or sell HCA Healthcare stock right now?

Does HCA Healthcare's stock price have much upside?

Has HCA Healthcare been downgraded by Wall Street analysts recently?

What analysts cover HCA Healthcare?

Do Wall Street analysts like HCA Healthcare more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

HCA Healthcare
Bull Case

HCA Healthcare
Bear Case